Adagene Inc.
Adagene Inc. (ADAG) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ADAG · as of Jun 9, 2026
Key Statistics
Explore Adagene Inc. Data
adag stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 100.0%
The ADAG analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $5.00, representing +53.37% upside from the current price of $3.26.
Competitors & Peers
adag competitorsADAG
ACET
CRVO
FBIO
GANX
LITSStock Performance
Full HistoryAbout Adagene Inc.
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineere…
what is adagene inc. · adag stock overview · adagene inc. company profile · who is adagene inc. ceo · adag NASDAQ · adagene inc. headquarters · adagene inc. business segments
About Stock Overview & Key Data
Adagene Inc. (ADAG) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 9, 2021. As of the latest trading session, ADAG stock price is $3.26, with a market capitalization of $122.7M. The stock has returned +70.68% over the past 12 months and +72.49% year-to-date.
According to 5 Wall Street analysts, the consensus rating for Adagene Inc. stock is Buy, with an average 12-month price target of $5.00. In fiscal year 2025, Adagene Inc. reported revenue of $7.7M and net income of -$17.6M. For detailed data — including Adagene Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Adagene Inc. (ADAG) stock price is $3.26. The stock is traded on NASDAQ under the ticker symbol ADAG. The 52-week range is $1.30 – $4.75.